Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include creamer and chocolate systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, ice cream bases and variegates, cereals, grain based snacks, and cereal based ingredients. This segment also offers microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. Its Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The company's Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. It also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company's Industrial Products segment provides choline chloride derivatives for hydraulic fracturing of shale natural gas wells; and methylamines, which are building blocks for the manufacture of choline products, as well as used in industrial applications. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was founded in 1967 and is headquartered in New Hampton, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
SectorBasic Materials
Current SymbolNASDAQ:BCPC
Previous Symbol
CUSIP05766520
Phone845-326-5600
Debt
Debt-to-Equity Ratio0.27
Current Ratio3.42
Quick Ratio2.33
Price-To-Earnings
Trailing P/E Ratio31.08
Forward P/E Ratio32.09
P/E GrowthN/A
Sales & Book Value
Annual Sales$594.79 million
Price / Sales4.26
Cash Flow$3.8226 per share
Price / Cash Flow20.57
Book Value$19.27 per share
Price / Book4.08
Profitability
EPS (Most Recent Fiscal Year)$2.53
Net Income$90.07 million
Net Margins15.67%
Return on Equity14.51%
Return on Assets9.67%
Miscellaneous
Employees1,165
Outstanding Shares32,250,000
Market Cap$2.61 billion
OptionableOptionable
Balchem (NASDAQ:BCPC) Frequently Asked Questions
What is Balchem's stock symbol?
Balchem trades on the NASDAQ under the ticker symbol "BCPC."
How often does Balchem pay dividends? What is the dividend yield for Balchem?
Balchem announced an annual dividend on Wednesday, December 13th. Stockholders of record on Wednesday, December 27th will be given a dividend of $0.42 per share on Friday, January 19th. This represents a dividend yield of 0.5%. The ex-dividend date is Tuesday, December 26th. This is a positive change from Balchem's previous annual dividend of $0.38. View Balchem's Dividend History.
How were Balchem's earnings last quarter?
Balchem Co. (NASDAQ:BCPC) posted its quarterly earnings results on Tuesday, November, 6th. The basic materials company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.12. The basic materials company had revenue of $155.04 million for the quarter, compared to analyst estimates of $163.66 million. Balchem had a return on equity of 14.51% and a net margin of 15.67%. The firm's revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 earnings per share. View Balchem's Earnings History.
When is Balchem's next earnings date?
What price target have analysts set for BCPC?
4 Wall Street analysts have issued 1 year target prices for Balchem's stock. Their forecasts range from $100.00 to $127.00. On average, they anticipate Balchem's stock price to reach $109.3333 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View Analyst Price Targets for Balchem.
What is the consensus analysts' recommendation for Balchem?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Balchem.
What are Wall Street analysts saying about Balchem stock?
Here are some recent quotes from research analysts about Balchem stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a comparable universe-derived P/E multiple approach to determine our price target. Applying a roughly 46x P/E multiple to our 2019 diluted EPS of $3.03, we derive a price objective of $140 per share." (10/15/2018)
- 2. Pivotal Research analysts commented, "We are raising our adjusted EPS estimates to $3.05 for 2018 and $3.35 for 2019 ($2.95 and $3.20 previously). We continue to view the company as very attractive, but the shares remain fully-priced. We are boosting our price target to $95 from $85 based on 28.4x 2019 EPS; The shares trade today at 19.3x EV/EBITDA. FCF yield is only 3%. BCPC has done a superb job, we can only hope for a better entry point." (8/3/2018)
Has Balchem been receiving favorable news coverage?
Media headlines about BCPC stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Balchem earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the basic materials company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Are investors shorting Balchem?
Balchem saw a drop in short interest in October. As of October 31st, there was short interest totalling 720,107 shares, a drop of 26.8% from the October 15th total of 983,256 shares. Based on an average daily volume of 139,780 shares, the short-interest ratio is presently 5.2 days. Approximately 2.2% of the shares of the stock are short sold. View Balchem's Current Options Chain.
Who are some of Balchem's key competitors?
Some companies that are related to Balchem include Johnson Matthey (JMPLY), KURARAY CO LTD/ADR (KURRY), Ashland Global (ASH), Chemours (CC), Huntsman (HUN), W. R. Grace & Co (GRA), Ingevity (NGVT), Olin (OLN), Univar (UNVR), PQ Group (PQG), GCP Applied Technologies (GCP), Innospec (IOSP), KMG Chemicals (KMG), Nexeo Solutions (NXEO) and Innophos (IPHS).
Who are Balchem's key executives?
Balchem's management team includes the folowing people:
- Mr. Theodore L. Harris, Chairman and Chief Exec. Officer (Age 53)
- Ms. Mary Theresa Coelho, Chief Financial Officer and Treasurer (Age 56)
- Mr. William A. Backus CPA, Chief Accounting Officer (Age 52)
- Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
- Mr. David F. Ludwig, VP & Gen. Mang. of Industrial Products (Age 60)
Who are Balchem's major shareholders?
Balchem's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.43%), Vanguard Group Inc. (10.09%), Wasatch Advisors Inc. (2.40%), Conestoga Capital Advisors LLC (2.33%), Dimensional Fund Advisors LP (2.28%) and Neuberger Berman Group LLC (2.13%). Company insiders that own Balchem stock include Daniel E Knutson, Edward Mcmillan and William A Backus. View Institutional Ownership Trends for Balchem.
Which institutional investors are selling Balchem stock?
BCPC stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Tributary Capital Management LLC, Wasatch Advisors Inc., Thrivent Financial for Lutherans, Eaton Vance Management, Summit Creek Advisors LLC, Strs Ohio and Eagle Asset Management Inc.. View Insider Buying and Selling for Balchem.
Which institutional investors are buying Balchem stock?
BCPC stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Conestoga Capital Advisors LLC, Vanguard Group Inc., Macquarie Group Ltd., First Trust Advisors LP, Standard Life Aberdeen plc, Standard Life Aberdeen plc and Renaissance Technologies LLC. View Insider Buying and Selling for Balchem.
How do I buy shares of Balchem?
Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Balchem's stock price today?
One share of BCPC stock can currently be purchased for approximately $78.63.
How big of a company is Balchem?
Balchem has a market capitalization of $2.61 billion and generates $594.79 million in revenue each year. The basic materials company earns $90.07 million in net income (profit) each year or $2.53 on an earnings per share basis. Balchem employs 1,165 workers across the globe.
What is Balchem's official website?
How can I contact Balchem?
Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at 845-326-5600 or via email at [email protected]
MarketBeat Community Rating for Balchem (NASDAQ BCPC)
MarketBeat's community ratings are surveys of what our community members think about Balchem and other stocks. Vote "Outperform" if you believe BCPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
